Lundbeck places Lu AA39959 trial on hold

H. Lundbeck A/S (CSE:LUN) disclosed in its 1Q09 earnings report on Wednesday that it placed on hold a Phase II trial of Lu AA39959 for bipolar disorder in order to implement a lower dose. The company ...